Literature DB >> 25101531

Antiretroviral therapy and the kidney.

Christina M Wyatt1.   

Abstract

Acute kidney injury (AKI) and chronic kidney disease (CKD) are more common in the HIV-infected population than in the general population. AKI is associated with an increased risk of heart failure, cardiovascular disease, end-stage renal disease (ESRD), and mortality. Tenofovir is associated with severe AKI in a small percentage of patients and with subclinical abnormalities in many more. HIV-associated nephropathy is now a relatively rare form of CKD, because of the widespread use of potent antiretroviral therapy. The CKD spectrum in HIV-infected patients has become more frequently characterized by comorbid CKD, with an increased frequency of CKD related to diabetes or hypertension being observed. Kidney transplantation is a therapeutic option for HIV-infected patients with ESRD if their HIV infection is controlled, although rates of acute graft rejection and drug-drug interactions are high. This article summarizes a presentation by Christina M. Wyatt, MD, at the IAS-USA continuing education program held in Washington, DC, in June 2013.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25101531      PMCID: PMC6148885     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  22 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech
Journal:  Clin Infect Dis       Date:  2005-04-22       Impact factor: 9.079

Review 3.  Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Authors:  Ryan D Cooper; Natasha Wiebe; Nathaniel Smith; Philip Keiser; Saraladevi Naicker; Marcello Tonelli
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

4.  Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.

Authors:  Paolo Maggi; Vincenzo Montinaro; Chiara Bellacosa; Stefania Pietanza; Anna Volpe; Giusi Graziano; Giovanni F M Strippoli; Gioacchino Angarano
Journal:  AIDS Patient Care STDS       Date:  2011-12-02       Impact factor: 5.078

5.  Outcomes of kidney transplantation in HIV-infected recipients.

Authors:  Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland
Journal:  N Engl J Med       Date:  2010-11-18       Impact factor: 91.245

6.  Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.

Authors:  Andrew M Hall; Simon G Edwards; Marta Lapsley; John O Connolly; Kreesan Chetty; Stephen O'Farrell; Robert J Unwin; Ian G Williams
Journal:  Am J Kidney Dis       Date:  2009-09-23       Impact factor: 8.860

7.  Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy?

Authors:  Tejinder S Ahuja; Neil Collinge; James Grady; Shilpi Khan
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

8.  Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Judith A Aberg; Joel E Gallant; Khalil G Ghanem; Patricia Emmanuel; Barry S Zingman; Michael A Horberg
Journal:  Clin Infect Dis       Date:  2014-01       Impact factor: 9.079

9.  Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

Authors:  Tomas Cihlar; Adrian S Ray; Genevieve Laflamme; Jennifer E Vela; Leah Tong; Michael D Fuller; Anupma Roy; Gerald R Rhodes
Journal:  Antivir Ther       Date:  2007

10.  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

Authors:  Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney
Journal:  AIDS       Date:  2007-06-19       Impact factor: 4.177

View more
  1 in total

1.  Combination ART-Induced Oxidative/Nitrosative Stress, Neurogenic Inflammation and Cardiac Dysfunction in HIV-1 Transgenic (Tg) Rats: Protection by Mg.

Authors:  I Tong Mak; Joanna J Chmielinska; Christopher F Spurney; William B Weglicki; Jay H Kramer
Journal:  Int J Mol Sci       Date:  2018-08-15       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.